IONIS PHARMACEUTICALS INC 4

EVP Eugene Schneider exercised 26,000 Ionis Pharmaceuticals stock options at ~$60.89 and sold the 26,000 resulting shares at a weighted average price of ~$81.05 on June 26, 2026 under a Rule 10b5-1 plan.

On June 26, 2026, Eugene Schneider, EVP and Chief Clinical Development Officer of Ionis Pharmaceuticals, Inc., exercised 26,000 non-qualified stock options at an exercise price of approximately $60.89 per share, acquiring 26,000 shares of common stock, and on the same day sold all 26,000 shares at a weighted average price of about $81.046 per share pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2025. The option exercise increased his direct common stock holdings to 103,114 shares, and the subsequent sale reduced his holdings to 77,114 shares. The gross sale proceeds were roughly $2.11 million, implying an approximate spread of $20.16 per share between the option exercise price and sale price, and representing a sizable, pre-planned liquidity event but not a net increase in his ownership stake.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000216

Alert Tier

6